{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:46:17Z","timestamp":1790621177138,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Tafamidis treatment positively affects left ventricular (LV) structure and function and improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). We aimed to investigate the relationship between treatment response and cardiac amyloid burden identified by serial quantitative 99mTc-DPD SPECT\/CT. We furthermore aimed to identify nuclear imaging biomarkers that could be used to quantify and monitor response to tafamidis therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Forty wild-type ATTR-CM patients who underwent 99mTc-DPD scintigraphy and SPECT\/CT imaging at baseline and after treatment with tafamidis 61 mg once daily [median, 9.0 months (interquartile range 7.0\u201310.0)] were divided into two cohorts based on the median (\u221232.3%) of the longitudinal percent change in standardized uptake value (SUV) retention index. ATTR-CM patients with a reduction greater than or equal to the median (n = 20) had a significant decrease in SUV retention index (P &amp;lt; 0.001) at follow-up, which translated into significant benefits in serum N-terminal prohormone of brain natriuretic peptide levels (P = 0.006), left atrial volume index (P = 0.038), as well as LV [LV global longitudinal strain: P = 0.028, LV ejection fraction (EF): P = 0.027, LV cardiac index (CI): P = 0.034] and right ventricular (RV) [RVEF: P = 0.025, RVCI: P = 0.048] functions compared with patients with a decrease less than the median (n = 20).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with tafamidis in ATTR-CM patients results in a significant reduction in SUV retention index, associated with significant benefits for LV and RV function and cardiac biomarkers. Serial quantitative 99mTc-DPD SPECT\/CT imaging with SUV may be a valid tool to quantify and monitor response to tafamidis treatment in affected patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Translational perspective<\/jats:title>\n                  <jats:p>99mTc-DPD SPECT\/CT imaging with determination of SUV retention index as part of a routine annual examination can provide evidence of treatment response in ATTR-CM patients receiving disease-modifying therapy. Further long-term studies with 99mTc-DPD SPECT\/CT imaging may help to evaluate the relationship between tafamidis-induced reduction in SUV retention index and outcome in patients with ATTR-CM and will demonstrate whether highly disease-specific 99mTc-DPD SPECT\/CT imaging is more sensitive than routine diagnostic monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjci\/jead030","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T20:45:21Z","timestamp":1678221921000},"page":"1019-1030","source":"Crossref","is-referenced-by-count":71,"title":["Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-5158","authenticated-orcid":false,"given":"Ren\u00e9","family":"Rettl","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wollenweber","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Duca","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Binder","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Cherouny","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-7608","authenticated-orcid":false,"given":"Theresa-Marie","family":"Dachs","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Camuz Ligios","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-2667","authenticated-orcid":false,"given":"Lore","family":"Schrutka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-5745","authenticated-orcid":false,"given":"Daniel","family":"Dalos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-3827","authenticated-orcid":false,"given":"Dietrich","family":"Beitzke","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-0676","authenticated-orcid":false,"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Badr Eslam","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kastner","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-7910","authenticated-orcid":false,"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 , Austria"},{"name":"Division of Cardiology, Department of Internal Medicine V, Favoriten Clinic , Kundratstra\u00dfe 3, 1100 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"2023072413350635800_jead030-B1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2023072413350635800_jead030-B2","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023072413350635800_jead030-B3","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2023072413350635800_jead030-B4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/MNM.0000000000000586","article-title":"Activity concentration measurements using a conjugate gradient (Siemens xSPECT) reconstruction algorithm in SPECT\/CT","volume":"37","author":"Armstrong","year":"2016","journal-title":"Nucl Med Commun"},{"key":"2023072413350635800_jead030-B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-018-0367-7","article-title":"A new SPECT\/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases","volume":"8","author":"Delcroix","year":"2018","journal-title":"EJNMMI Res"},{"key":"2023072413350635800_jead030-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9113446","article-title":"In vivo quantification of myocardial amyloid deposits in patients with suspected transthyretin-related amyloidosis (ATTR)","volume":"9","author":"Wollenweber","year":"2020","journal-title":"J Clin Med"},{"key":"2023072413350635800_jead030-B7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2023072413350635800_jead030-B9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","article-title":"Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement","volume":"132","author":"Bonderman","year":"2020","journal-title":"Wien Klin Wochenschr"},{"key":"2023072413350635800_jead030-B10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4\u00d720-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023072413350635800_jead030-B11","first-page":"1","article-title":"ATS Statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2023072413350635800_jead030-B12","first-page":"1","article-title":"Introduction to xSPECT technology: evolving multi-modal SPECT to become context-based and quantitative","author":"Vija","year":"2013","journal-title":"Siemens Medical Solutions USA, Inc., Molecular Imaging, White Pap"},{"key":"2023072413350635800_jead030-B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","article-title":"Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population","volume":"2","author":"Ramsay","year":"2018","journal-title":"Eur J Hybrid Imaging"},{"key":"2023072413350635800_jead030-B14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023072413350635800_jead030-B16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"2023072413350635800_jead030-B17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcmg.2015.11.002","article-title":"T1 mapping by CMR imaging from histological validation to clinical implication","volume":"9","author":"Kammerlander","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update","volume":"22","author":"Kramer","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023072413350635800_jead030-B20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023072413350635800_jead030-B21","article-title":"The use of SPECT\/CT quantification of 99mTc-PYP uptake to assess tafamidis treatment response in ATTR cardiac amyloidosis","volume":"22","author":"Elsadany","year":"2021","journal-title":"Eur Hear J Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaccas.2020.11.036","article-title":"First follow-up of cardiac amyloidosis treated by tafamidis, evaluated by absolute quantification in bone scintigraphy","volume":"3","author":"Bellevre","year":"2021","journal-title":"JACC Case Reports"},{"key":"2023072413350635800_jead030-B23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B24","first-page":"1","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2022","journal-title":"Amyloid"},{"key":"2023072413350635800_jead030-B25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ehjci\/jey225","article-title":"Mechanisms of heart failure in transthyretin vs. light chain amyloidosis","volume":"20","author":"Binder","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023072413350635800_jead030-B26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"key":"2023072413350635800_jead030-B27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","article-title":"Cardiac magnetic resonance T 1 mapping in cardiac amyloidosis","volume":"11","author":"Duca","year":"2018","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/24\/8\/1019\/50946333\/jead030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/24\/8\/1019\/50946333\/jead030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:36:18Z","timestamp":1690205778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/24\/8\/1019\/7070981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jead030","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,3,7]]}}}